SCHEMBL710664

SCHEMBL710664

c1ccc(COc2cc(OCc3ccccc3)cc(-c3nc4cc(-c5ccccc5)cnc4[nH]3)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 3/20 0.46
CHEK2 O96017 1/20 0.43
IP6K1 Q92551 1/20 0.43
AXL P30530 1/20 0.42
CDK8 P49336 1/20 0.42
PRMT5 O14744 4/20 0.41
ALOX5 P09917 2/20 0.41
CYP3A4 P08684 1/20 0.41
KDM4E B2RXH2 2/20 0.41
MAPT P10636 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL710173 0.92 GCK (0.44) DHODHCHEK2IP6K1AXLCDK8
SCHEMBL719830 0.85 MCL1 (0.43) DHODHCHEK2PRMT5CYP3A4KDM4E
SCHEMBL711343 0.84 GCK (0.41) DHODHEGLN1MAOB
SCHEMBL711037 0.84 PRMT5 (0.44) CHEK2PRMT5CYP3A4KDM4EMAPT
SCHEMBL10206538 0.84 MAPT (0.42) DHODHCHEK2IP6K1PRMT5ALOX5
SCHEMBL712755 0.84 MEN1 (0.53) DHODHCHEK2KDM4EALDH1A1HPGD
SCHEMBL10206527 0.84 MAPT (0.45) CHEK2IP6K1ALOX5CYP3A4KDM4E
SCHEMBL10206641 0.82 PRMT5 (0.51) DHODHCHEK2PRMT5ALOX5CYP3A4
SCHEMBL2668214 0.82 CHEK2 (0.48) DHODHCHEK2PRMT5ALDH1A1SMN1; SMN2
SCHEMBL711270 0.81 GRIN1 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK DHODH 910/4885CHEK2 1189/4885IP6K1 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.